Our results suggest that PERK plays a pivotal role in mediating eIF2α phosphorylation responsible for BACE1 and ATF4 elevations associated with β-amyloidosis and that the GCN2 pathway may function as a negative regulator of PERK-dependent eIF2α phosphorylation under AD conditions. Here, EIF2A is linked to Alzheimer disease.